Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial

Abstract

Background Lysyl oxidase-like 2 (LOXL2) catalyses collagen cross-linking and is implicated in the pathogenesis of idiopathic pulmonary fibrosis (IPF). The aim of this study was to investigate the efficacy and safety of simtuzumab, a monoclonal antibody against LOXL2, in patients with IPF. Methods In this randomised, double-blind, phase 2 trial, we recruited patients aged 45-85 years with definite IPF diagnosed prior to 3 years of screening from 183 hospitals and respiratory clinics in 14 countries. Eligible patients, stratified by baseline forced vital capacity (FVC), serum LOXL2 (sLOXL2) concentrations, and pirfenidone and nintedanib use, were randomly assigned (1:1) to inject 125 mg/mL simtuzumab or placebo subcutaneously once a week. The primary endpoints were progression-free survival, defined as time to all-cause death or a categorical decrease from baseline in FVC % predicted, in the intention-to-treat population, in patients with sLOXL2 concentrations in the 50th percentile or higher, and in patients with sLOXL2 concentrations in the 75th percentile or higher. Treatment duration was event-driven, and interim analyses were planned and conducted after approximately 120 and 200 progression-free survival events, respectively, occurred. We compared treatment groups with the stratified log-rank test. This study is registered with ClinicalTrials.gov, number NCT01769196. Findings Patients with IPF were recruited between Jan 31, 2013, and June 1, 2015. The intention-to-treat po…

Overview

Integrity signals

Registry

Crossref · 10.1016/s2213-2600(16)30421-0

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 17 references

Cited by

See all 284

Metadata

Authors
Raghu, G., Brown, K. K., Collard, H. R., Cottin, V., Gibson, K. F., Kaner, R. J., Lederer, D. J., Martinez, F. J., Noble, P. W., Song, J. W., Wells, A. U., Whelan, T. P. M., Wuyts, W., Moreau, E., Patterson, S. D., Smith, V., Bayly, S., Chien, J. W., Gong, Q., Zhang, J. J., & O'Riordan, T. G.
Affiliations
  • University of Washington (US)
  • University of California, San Francisco (US)
  • Université de Lyon (FR)
  • University of Pittsburgh (US)
  • Weill Cornell Medicine (US)
  • Columbia University Irving Medical Center (US)
  • Cedars-Sinai Medical Center (US)
  • Asan Medical Center (KR)
  • Royal Brompton Hospital (GB)
  • Medical University of South Carolina (US)
  • KU Leuven (BE)
  • bioMérieux (France) (FR)
  • Gilead Sciences (United States) (US)
Corresponding author
Raghu, Ganesh
Venue
The Lancet Respiratory Medicine
Publisher
Elsevier BV
Published
2017-01
Volume
5
Issue
1
Pages
22-32
ISSN
2213-2600 (ISSN-L)
OpenAlex
W2560640434
Cited by
278
References
17
Citations by year
2026: 24 · 2025: 16 · 2024: 36 · 2023: 26 · 2022: 25 · 2021: 21 · 2020: 27 · 2019: 29 · 2018: 40 · 2017: 32
FWCI
30.17
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet Respiratory Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Lirias (submittedVersion)
Funders
Gilead Sciences
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
Keywords
idiopathic pulmonary fibrosis, LOXL2, monoclonal antibodies, collagen cross-linking, progression-free survival, forced vital capacity decline, treatment safety, anti-drug antibodies, pulmonary hypertension, pulmonary arterial hypertension
MeSH terms
Aged, Aged, 80 and over, Amino Acid Oxidoreductases, Double-Blind Method, Drug Administration Schedule, Enzyme Inhibitors, Female, Humans, Indoles, Male, Middle Aged, Pyridones, Treatment Outcome, Disease-Free Survival, Idiopathic Pulmonary Fibrosis, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial. https://app.cochat.ai/papers/10.1016/s2213-2600(16)30421-0
The paper
Raghu, G., Brown, K. K., Collard, H. R., Cottin, V., Gibson, K. F., Kaner, R. J., Lederer, D. J., Martinez, F. J., Noble, P. W., Song, J. W., Wells, A. U., Whelan, T. P. M., Wuyts, W., Moreau, E., Patterson, S. D., Smith, V., Bayly, S., Chien, J. W., Gong, Q., . . . O'Riordan, T. G. (2017). Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial. The Lancet Respiratory Medicine. https://doi.org/10.1016/s2213-2600(16)30421-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.